肥胖、营养不良与炎症指标可强预测2型糖尿病成人死亡率:FIELD研究
该研究基于FIELD研究中9550例2型糖尿病成人5年随访数据,采用基线血浆NMR代谢组学指标MVX及其组分IVX、MMX评估与死亡及非致死事件关联。结果显示MVX最高五分位者未调整死亡风险超四倍,调整后HR 2.31(95%CI 1.71,3.12),每增加1个标准差死亡风险升高75%(95%CI 62,89;p<0.001)。MVX独立预测总死亡和心血管死亡,并改善风险模型区分度(C统计量0.725至0.737;p=0.0003)。
要点
- MVX最高五分位者调整后死亡风险为最低五分位的2.31倍(95%CI 1.71,3.12)。
- MVX每升高1个标准差,总死亡风险增加75%(95%CI 62,89;p<0.001)。
- MVX改善风险模型区分度(C统计量0.725至0.737;p=0.0003),优于既往CVD史。
核心结论
- MVX可独立预测2型糖尿病患者的全因死亡和心血管死亡,提供超越传统危险因素的预后价值。
研究设计与样本
- 基于FIELD研究(1997-2000年招募)9550例2型糖尿病成人,随访5年,基线血浆NMR衍生MVX、IVX和MMX。
- 采用Cox模型调整临床变量和治疗分配,评估与死亡及非致死事件的关联,并用C统计量和变量贡献分析评估预测性能。
主要发现
- MVX最高五分位(Q5)未调整死亡风险为最低五分位的四倍以上,调整后HR 2.31(95%CI 1.71,3.12)。
- MVX每增加1个标准差,死亡风险增加75%(95%CI 62,89;p<0.001)。
- MVX分别与心血管死亡和癌症死亡相关,并独立预测非致死性心血管事件和新发癌症。
- MMX和IVX的关联较弱且不一致。
- MVX改善风险模型区分度(C统计量0.725至0.737;p=0.0003),且优于既往CVD史作为预测因子。
临床怎么用
- MVX可作为2型糖尿病患者的预后评估工具,辅助识别传统危险因素之外的高死亡风险个体。
- 结果支持进一步研究MVX在个性化风险判定中的临床效用。
局限性
- 绝对事件率反映FIELD招募期(1997-2000年)的治疗标准,早于多种当代心脏保护疗法的广泛使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Metabolic risk in type 2 diabetes is not fully captured by standard clinical measures. Use of NMR-based metabolomic indices may enhance risk prediction, but their role in individuals with type 2 diabetes is unresolved. METHODS: We analysed data from 9550 adults with type 2 diabetes who were followed for 5 years in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. The composite index MVX (metabolic vulnerability), and its components IVX (inflammation vulnerability index) and MMX (metabolic malnutrition index), were derived from baseline plasma NMR. Associations with mortality and non-fatal events were assessed using Cox models adjusted for clinical variables and treatment allocation. Predictive performance was assessed using C statistics and variable contribution analysis. RESULTS: All three indices were associated with total mortality. Participants in the highest MVX quintile (Q5) had an over fourfold greater unadjusted mortality risk, and more than double the risk after adjustment (HR 2.31; 95% CI 1.71, 3.12). Each standard deviation increase in MVX showed a 75% higher mortality risk (95% CI 62, 89; p<0.001). MVX was associated with cardiovascular and cancer mortality separately, and independently predicted non-fatal cardiovascular events and new incident cancer. MMX and IVX showed weaker and less consistent associations. MVX improved risk model discrimination (C statistic 0.725 to 0.737; p=0.0003) and outperformed prior CVD history as a predictor. CONCLUSIONS/INTERPRETATION: MVX independently predicts total and cardiovascular mortality in type 2 diabetes, offering prognostic value beyond traditional risk factors. The absolute event rates reflect the treatment standards of the FIELD recruitment period (1997-2000), prior to widespread use of several contemporary cardioprotective therapies. The results support further investigation of the clinical utility of MVX for determination of personalised risk.
引用
- Keech AC, O'Connell RL, Januszewski AS, et al. Indices of obesity, malnutrition and inflammation are strong predictors of mortality in adults with type 2 diabetes: the FIELD study. Diabetologia. 2026. PMID: 42752966. doi:10.1007/s00125-026-06848-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。